Skip to content
Send your media release — 9:00am to 3:30pm AEST, Mon to Fri Australian owned & operated — based in Brisbane
Press release distribution Australia-wide
Newsroom

Press release

MEDLAB offers strong insights to 1100 Australian needing pain control

Issued by Dr Sean Hall of Medlab Clinical LTD

MEDLAB CLINICAL (not Pathology) announces specialised cannabis pain management interim results for 1172 Australian pain patients.

Dr Hall states “not all cannabis products are the same, but this proprietary formulation with a very specific, novel delivery platform showed incredible benefit in 1172 Australians”

55% improvement in pain relief, 75% of patients reduced their opioids, 31% improvement in quality of life.

Whilst the study was a RWE (Real World Evidence Study), similar to a Phase 4 post market study, the real world component showed strong alignment to prior clinical results.

244 Australian Doctors attended the patient group an collect data for up to a 12 month period, demonstrating sustainability and confidence as the company moves forward in its clinical package for drug registration.

About Medlab Clinical:
Medlab Clinical LTD (ASX:MDC) is pioneering the use of NanoCelle® a proprietary, patented delivery technology using water soluble nanoparticles®, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability. Medlab’s investigative drug pipeline comprises several small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. Patented lead drug candidate NanaBis™ is being developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis™ may be equally effective in non-cancer neuropathic pain. Medlab operates in Australia (Head Office), USA, and the UK.

About Dr Sean Hall of Medlab Clinical LTD

About Medlab Clinical: Medlab Clinical LTD (ASX:MDC) is pioneering the use of NanoCelle® a proprietary, patented delivery technology using water soluble nanoparticles®, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability. Medlab’s investigative drug pipeline comprises several small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. Patented lead drug candidate NanaBis™ is being developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis™ may be equally effective in non-cancer neuropathic pain. Medlab operates in Australia (Head Office), USA, and the UK.

Visit website

More press releases

View all in the newsroom

DLP declares itself right-wing Labour

Democratic Labour Party (DLP) Victoria

A new political philosophy puts the family ahead of government and the working household ahead of big corporations, and publishes the test every policy must…

No good news should go unpublished

Ready to share your media release with Australian journalists? It’s fast, simple and takes just minutes.

Have a question? Contact our Brisbane team.

Get The Word Out acknowledges the Turrbal and Jagera peoples as the Traditional Custodians of Meanjin (Brisbane), where we are based. We recognise their continuing connection to land, waters and community, and pay our respects to Elders past and present. We extend this respect to all Aboriginal and Torres Strait Islander peoples.